Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.
Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...
Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Viral Vector Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Viral Vector ...
Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...
WEST PALM BEACH, FL, Sept. 22, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTCID: FOXO) (“FOXO” or the “Company”), announces the closing of the acquisition of Vector Biosource Inc. (“Vector”).
TAMPA, FL and BLOOMINGTON, IN - (Sept. 8, 2021) - Vector Solutions, the leading provider of industry-focused software solutions for training, workforce management and risk communications, has acquired ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback